Information Disclosure Issues Challenge FDA Transparency Task Force
This article was originally published in The Tan Sheet
Executive Summary
FDA questions whether to disclose information on product applications that a company abandons before approval or in some cases on applications in which review is still pending
You may also be interested in...
FDA Launches System To Track Performances of Its Offices
For those wondering how many adverse events reports FDA received last month, the number of Risk Evaluation and Mitigation Strategies it cleared or the number of first generics it approved, the answers are now readily accessible
Transparency Initiative In "What Is The Right Thing To Do" Phase - Sharfstein
In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process more accessible to the public. The agency held two public meetings and solicited comments; the docket closed Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to Elsevier Business Intelligence's "The Pink Sheet" about its initial findings.
FDA To Address Industry Questions In Transparency Effort
FDA has expanded its transparency initiative to cover an unanticipated area - explaining how the agency works to the industries it regulates